d'Ettorre G - Search Results

1

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.

Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Fabbiani M, et al. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. J Antimicrob Chemother. 2018. PMID: 29668978 Clinical Trial.

2

Circulating levels of interleukin-7 in antiretroviral-naïve and highly active antiretroviral therapy-treated HIV-infected patients.

Mastroianni CM, Forcina G, d'Ettorre G, Lichtner M, Mengoni F, D'Agostino C, Vullo V. Mastroianni CM, et al. HIV Clin Trials. 2001 Mar-Apr;2(2):108-12. doi: 10.1310/6V29-4UU5-Y3FP-JERT. HIV Clin Trials. 2001. PMID: 11590518 Clinical Trial.

3

Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M. Nicastri E, et al. J Med Virol. 2003 Jan;69(1):1-6. doi: 10.1002/jmv.10269. J Med Virol. 2003. PMID: 12436471

4

Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients.

Grelli S, d'Ettorre G, Lauria F, Montella F, Di Traglia L, Lichtner M, Vullo V, Favalli C, Vella S, Macchi B, Mastino A. Grelli S, et al. J Antimicrob Chemother. 2004 Mar;53(3):494-500. doi: 10.1093/jac/dkh105. Epub 2004 Feb 12. J Antimicrob Chemother. 2004. PMID: 14963063 Clinical Trial.

5

Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.

d'Ettorre G, Zaffiri L, Ceccarelli G, Andreotti M, Massetti AP, Vella S, Mastroianni CM, Vullo V. d'Ettorre G, et al. HIV Clin Trials. 2007 May-Jun;8(3):182-8. doi: 10.1310/hct0803-182. HIV Clin Trials. 2007. PMID: 17621465 Clinical Trial.

6

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group. Baroncelli S, et al. Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6. Ann Pharmacother. 2010. PMID: 20371753 Clinical Trial.

7

The role of HIV-DNA testing in clinical practice.

d'Ettorre G, Zaffiri L, Ceccarelli G, Mastroianni CM, Vullo V. d'Ettorre G, et al. New Microbiol. 2010 Jan;33(1):1-11. New Microbiol. 2010. PMID: 20402409 Free article. Review.

8

Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, D'Ettorre G, Parruti G, Prosperi M, Bracciale L, Cauda R, Navarra P, De Luca A. Fabbiani M, et al. Pharmacol Res. 2011 Mar;63(3):249-53. doi: 10.1016/j.phrs.2010.11.009. Epub 2010 Dec 2. Pharmacol Res. 2011. PMID: 21130167

9

Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy.

d'Ettorre G, Forcina G, Ceccarelli G, Andreotti M, Andreoni C, Rizza C, Massetti AP, Sarmati L, Mastroianni CM, Vella S, Andreoni M, Vullo V. d'Ettorre G, et al. J Chemother. 2011 Feb;23(1):24-7. doi: 10.1179/joc.2011.23.1.24. J Chemother. 2011. PMID: 21482490

10

Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy.

Ammassari A, Trotta MP, Shalev N, Tettoni MC, Maschi S, Di Sora F, Orofino G, d'Ettorre G, Bai F, Celesia MB, Quiros Roldan E, Maserati R, Sterrantino G, Tommasi C, Boumis E, Iardino MR, Antinori A. Ammassari A, et al. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e113-5. doi: 10.1097/QAI.0b013e3182359d2a. J Acquir Immune Defic Syndr. 2011. PMID: 22033235 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

346 results

Search Page